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Abstract
The influenza (“flu”) type-A virus is a major medical and veterinary health concern and causes global pandemics. The peptide
“FluPep” is an established inhibitor of influenza virus infectivity in model systems. We have explored the potential for noble-metal
nanoparticle conjugates of FluPep to enhance its antiviral activity and to determine their potential as a delivery platform for FluPep.
FluPep ligand is FluPep extended at its N-terminus with the sequence CVVVTAAA, to allow for its incorporation into a mixed-
matrix ligand shell of a peptidol and an alkanethiol ethylene glycol consisting of 70% CVVVTol and 30% HS(CH2)11(OC2H4)4OH
(mol/mol). Gold and silver nanoparticles (ca. 10 nm diameter) with up to 5% (mol/mol) FluPep ligand remained as stable as the
control of mixed-matrix-passivated nanoparticles in a variety of tests, including ligand exchange with dithiothreitol. The free
FluPep ligand peptide was found to inhibit viral plaque formation in canine MDCK cells (IC50 = 2.1 nM), but was less potent than
FluPep itself (IC50 = 140 pM). Nanoparticles functionalised with FluPep ligand showed enhanced antiviral activity compared to the
free peptides. The IC50 value of the FluPep-functionalised nanoparticles decreased as the grafting density of FluPep ligand in-
creased from 0.03% to 5% (both mol/mol), with IC50 values down to about 10% of that of the corresponding free peptide. The data
demonstrate that conjugation of FluPep to gold and silver nanoparticles enhances its antiviral potency; the antimicrobial activity of
silver ions may enable the design of even more potent antimicrobial inhibitors, capable of targeting both influenza and bacterial
co-infections.
Introduction
The influenza (“flu”) type-A virus is a major health concern for
humans and livestock animals. The primary mode of transmis-
sion is by the respiratory route. Flu infection occurs seasonally
and can cause global pandemics, e.g., the 2009 H1N1 subtype
swine influenza, which resulted in more than 18000 deaths
worldwide [1]. The treatment of influenza infections is difficult,
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because the virus has a segmented RNA genome that has a high
potential to recombine and create new strains through a mecha-
nism termed re-assortment [2]. Other potential risks to human
populations are the zoonotic avian (bird) and porcine (swine)
influenza viruses. Vaccination remains the most effective means
to prevent and control infection [3]. However, the lead time to
vaccine production is around nine months, efficacy is not
always complete, only a fraction of the human population is
vaccinated, and although some vaccines have been trialled
against avian influenza, farm animals in general are not
routinely vaccinated on a global scale [4]. There is, therefore,
the need for drugs to combat influenza infection in a more
effective and timely manner.
Currently there are two common types of anti-influenza drugs,
based on their mechanism of action. The first class are
neuraminidase inhibitors such as Oseltamivir (Tamiflu). The
second class are virus ion-channel blockers, such as Amanta-
dine (Symetrel). The effectiveness of Tamiflu has been ques-
tioned [5], and in any case the emerging resistance of the
influenza virus is leading to reduced effectiveness [6]. The
promise of peptide-based antiviral drugs has been established
by the approval of the Food and Drug Administration (USA) of
Enfuvirtidie against HIV [7]. The potential therapeutic use of
other antiviral peptides has been demonstrated in HIV [8,9],
hepatitis C [10], herpes simplex [11,12], influenza virus [13-
15].
The infectivity of influenza A viruses, including the H1N1
subtype, is strongly inhibited by a peptide called FluPep [15].
FluPep was originally identified as a sequence in tyrosine
kinase inhibitor peptide (Tkip), thought to act as a mimic of the
suppressor of cytokine signalling (SOCS) protein [16]. Howev-
er, the antiviral activity of FluPep does not depend on blocking
cytokine signalling, which is intracellular, but instead this
peptide appears to exert its antiviral activity from the outside of
the cell. Thus, the addition of FluPep to cells in culture prevents
infection by influenza viruses, as does intranasal delivery of the
peptide in a murine model of human influenza [15].
Noble-metal nanoparticles possess a strong plasmon absor-
bance, which allows for the detection at very low levels, using a
range of approaches, from absorbance [17,18] to photothermal
microscopy [19] and various extensions of the latter [20,21].
Noble-metal nanoparticles can be passivated and functionalised
with biomolecules such that they possess the biological selec-
tivity and specificity of the grafted biological functional entity
[22], which includes peptides [23,24]. Presentation of a func-
tional peptide by means of a nanoparticle has a number of
advantages. Thus, nanoparticle conjugation may enhance the
solubility of the peptide, as well as enhance the biological activ-
ity of the peptide, for example, due to multivalent functionalisa-
tion of the nanoparticles. In addition, silver possesses innate
antimicrobial activities [25]. Thus, noble-metal nanoparticles
are potentially useful as both functional probes for antiviral
peptides and as therapeutic delivery platforms. We have, there-
fore, synthesized gold and silver nanoparticles functionalised
with FluPep and analysed the anti-influenza activity of the
nanoparticle–FluPep ligand conjugates. The results demon-
strate that the nanoparticle–FluPep ligand conjugates reduce the
infectivity of influenza virus with greater antiviral activity than
the free peptide, making this a viable tool for the development
of a peptide formulation that efficiently combats seasonal,
pandemic, and zoonotic influenza infections.
Results and Discussion
Stability of FluPep functionalised gold
nanoparticles
The mixed-matrix ligand shell of 70:30 (mol/mol) peptidol and
alkanethiol ethylene glycol assembled on gold nanoparticles has
a well-characterised stability with respect to ligand exchange
and non-specific binding [26,27], but the effect of incorporat-
ing the FluPep amino acid sequence at the C-terminus of the
CVVVT matrix sequence was unknown. Since the molcular
weight of FluPep ligand (2967 Da) is greater than that required
for group separation on Sephadex G25 (1000 Da), additional
purification by means of washes on a 10 kDa cut-off Nanosep
filter were included to ensure removal of any free FluPep
ligand. When up to 5% (mol/mol) FluPep ligand was incorpo-
rated in the ligand matrix, the gold nanoparticles still eluted in
the void volume of the Sephadex G25 column, so did not bind
non-specifically to this chromatography matrix, and their
UV–vis spectrum in PBS was indistinguishable from that of
control mixed-matrix gold nanoparticles (Figure 1A). This indi-
cates that the FluPep sequence did not reduce the stability of the
gold nanoparticles under these standard conditions. A more
stressful test is ligand exchange with small thiols [26-29]. The
ligand exchange results in a ligand shell that is unable to
prevent electrolyte-induced aggregation of the nanoparticles,
demonstrated by a decrease in the plasmon absorption at
520 nm.
Gold nanoparticles with a ligand shell incorporating
5% (mol/mol) FluPep ligand had a very similar resistance to
ligand exchange with DTT as the control mixed-matrix-pro-
tected gold nanoparticles. Their aggregation parameter was un-
changed up to 5 mM DTT, even after 48 h incubation
(Figure 1B,C). At 10 mM DTT after 48 h there was some evi-
dence for ligand exchange, as the aggregation parameter was
above 1.0 and at 25 mM DTT the ligand shell was clearly
compromised. Nanoparticles incorporating lesser amounts of
FluPep ligand (0.1% to 3% (mol/mol)) were no less stable (Sup-
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Figure 1: Stability of gold nanoparticles to DTT ligand exchange.
(A) UV–vis spectra of mixed-matrix-capped gold nanoparticles and
mixed-matrix-capped gold nanoparticles incorporating 5% (mol/mol)
FluPep ligand in PBS. Time- and dose-dependence of DTT ligand
exchange for (B) mixed-matrix gold nanoparticles and (C) gold nano-
particles with a ligand shell incorporating 5% (mol/mol) FluPep ligand.
Results in (B) and (C) are the mean ± SD (n = 3).
porting Information File 1, Figure S1A–F). Consequently, the
incorporation of up to 5% (mol/mol) FluPep ligand in the ligand
mixture did not reduce the stability of the gold nanoparticles
with respect to ligand exchange and such nanoparticles could be
used in cell culture medium.
Purification of functionalised gold
nanoparticles
When the peptide FluPep ligand was included in the ligand mix
to functionalise the nanoparticles, its molar fraction in percent
in relation to the matrix ligand should reflect its grafting densi-
ty on the gold nanoparticles [17,22,26,30-32]. This can be de-
termined by chromatography targeting specifically the grafted
function, which also provides a means to purify the function-
alised gold nanoparticles from those not functionalised, when
the molar fraction of the functional ligand is low. Thus, when
10% of the functionalised gold nanoparticles bind to the chro-
matography column, most of these (95%) will possess just one
grafted functional ligand [26,30]. Since FluPep ligand, when in-
corporated into a nanoparticle ligand shell, has a net charge at
pH 7.4 of +6, cation-exchange chromatography was used to
Figure 2: Purification of FluPep-ligand-functionalised gold nanoparti-
cles by CM-Sepharose cation-exchange chromatography. Chromatog-
raphy on CM-Sepharose was carried out with gold nanoparticles func-
tionalised with different molar fractions of FluPep ligand. Top: images
of columns after loading and washing with PBS. Bottom: quantification
by absorption at 450 nm [18] of unbound (flow-through and PBS wash
fractions) and bound (eluted with 2 M NaCl) fractions as a percentage
of total nanoparticles applied to the column. Results are the
mean ± SD (n = 3).
purify the functionalised gold nanoparticles. Parallel chroma-
tography was performed on the anion exchanger DEAE-
Sepharose to control for possible non-specific binding of
FluPep ligand to Sepharose.
Mixed-matrix gold nanoparticles did not to bind to either
CM-Sepharose or DEAE-Sepharose (Supporting Information
File 1, Figure S2), as described previously [26]. Similarly, when
FluPep ligand was incorporated in the ligand shell there was no
binding to DEAE-Sepharose, indicating an absence of non-spe-
cific interactions with the chromatography resin (Supporting
Information File 1, Figure S2). In contrast, the FluPep-function-
alised gold nanoparticles bound to CM-Sepharose and were
eluted by increasing electrolyte concentrations (Figure 2). Thus,
the FluPep-functionalised gold nanoparticles ion-exchanged on
this chromatography support, which is, therefore, suitable for
their purification. Gold nanoparticles were synthesised with a
range of molar fractions of FluPep ligand. After application of
the gold nanoparticles to the column, the non-functionalised
gold nanoparticles were collected in the flow-through and the
functionalised ones were then eluted. Quantification of the gold
nanoparticles by UV–vis spectrophotometry then allowed the
relation of bound and unbound gold nanoparticles to the molar
fraction of FluPep in the original ligand mixture to be analysed.
The data indicate that at 0.03 mol %, 10% of the gold nanoparti-
cles bound the column and thus most (ca. 95%) of these gold
nanoparticles will possess just one single FluPep ligand [30]. At
higher molar fractions the number of FluPep ligands per nano-
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particle will increase. It is interesting to note that not all gold
nanoparticles were observed to bind to the CM-Sepharose
column at higher molar fractions of FluPep ligand, something
that has been observed previously with other functional peptides
[31,32].
Anti-influenza activity of FluPep and FluPep
ligand
MDCK cells are susceptible to both influenza type-A and type-
B viruses and are routinely used to measure influenza virus
infectivity. The principle is that following influenza virus parti-
cle binding, the virion will enter the cell, replicate its genome,
translate viral protein components, assemble viral particles and
then egress from the infected cell by lysis. The released viral
particles will then infect neighbouring cells. By putting an
agarose overlay on cultured cells following incubation for 1 h
with the virus to initiate infection, long-range diffusion of the
virus is prevented, ensuring only neighbouring cells are infected
upon cell lysis. Consequently, after three days an area of lysed
cells is apparent, the so-called “plaque”, which is visualised as a
clear circle that does not stain with toluidine blue. In control (no
virus) and vehicle (DMSO)-treated cells, the cell monolayer in
the well was evenly stained (Supporting Information File 1,
Figure S3). In the presence of virus, there were substantial areas
where cells had lysed (plaques) and there was no staining. Virus
titre was adjusted so that the cleared lysed cell areas corre-
sponded to individual plaques, i.e., clear circles that could be
distinguished from one another and so be counted (correspond-
ing to ca. 100 plaques/well). In the presence of FluPep there
was a reduction in the number of plaques and this was concen-
tration-dependent (Figure 3). Counting plaques in multiple ex-
periments allowed for the determination of the dose response
and the IC50 values. In these experiments the IC50 value of the
original FluPep sequence was found to be of the order of
140 pM (Figure 3, inset). This is less potent than the value de-
scribed in the original publication, where an IC50 value of
14 pM was measured [15]. The source of this discrepancy is
unknown, but more than likely relates to differences in cells
such as passage number, and/or virus preparations. The FluPep
ligand, used to functionalise gold nanoparticles was slightly less
potent, with an IC50 value of around 210 pM, suggesting that
the N-terminal extension CVVVTAA reduced the antiviral ac-
tivity to some extent (Figure 3).
Anti-flu activity of FluPep-functionalised gold
nanoparticles
The addition of mixed-matrix-passivated nanoparticles as
control had no detrimental effect on viral infectivity, since their
addition to the cells did not change the number of plaques.
However, when purified mixed-matrix-capped gold nanoparti-
cles functionalised with 5% (mol/mol) FluPep ligand were
Figure 3: Determination of the half maximal inhibitory concentration
(IC50) of FluPep and and FluPep ligand in a plaque assay. Inhibition of
plaque formation as a function of the concentration of FluPep and
FluPep ligand. Inset: IC50 values. Results are the mean ± SD (n = 3).
Figure 4: Effect of gold nanoparticles functionalised with FluPep ligand
on influenza virus plaque formation. Inhibition of plaque formation as a
function of the concentration of gold nanoparticles functionalised with
different molar fractions of FluPep ligand in the ligand mixture. Results
and the mean ± SD (n = 3).
added, there was a marked decrease in the number of plaques,
i.e., a reduced virus infectivity (Figure 4). Thus, antiviral activi-
ty of FluPep ligand was maintained when it was conjugated to
gold nanoparticles.
For gold nanoparticles functionalised with 0.03% (mol/mol)
FluPep ligand, the number of plaques started to decrease at
20 pM gold nanoparticles and reached a minimum of approxi-
mately two to eight plaques at 200 pM (Figure 4). As the
grafting density of FluPep ligand was increased, so did the
antiviral activity, to reach a maximum at 5% (mol/mol) FluPep
(Figure 4). This is reflected by the decreased IC50 value, which
shows a 4.5-fold greater potency of nanoparticles function-
alised with 5% (mol/mol) FluPep ligand, when compared to
nanoparticles functionalised with just 0.03% (mol/mol) FluPep
ligand (Table 1). The nanoparticles were always purified by
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Table 1: IC50 values of gold nanoparticles functionalised with different
molar fractions of FluPep ligand.
mol % FluPep ligand IC50 (nM)
0.03% 0.073
0.1% 0.068
0.3% 0.058
1% 0.023
3% 0.016
5% 0.015
cation-exchange chromatography (Figure 2), so in all cases
nanoparticles had at least one FluPep ligand. Taken together,
these data indicate that the potency of FluPep ligand on the
nanoparticles is greater than that of free FluPep ligand and of
the native FluPep peptide (inset of Figure 3 and Table 1).
Stability of FluPep functionalised silver
nanoparticles
Silver has well-established antimicrobial properties [33]. It was
of interest to determine whether FluPep-functionalised silver
nanoparticles exhibited a similar anti-flu activity to their gold
counterparts. The mixed-matrix ligand shell has been shown to
impart good stability to silver nanoparticles [17]. First, the
effect of incorporating FluPep into the ligand shell on the nano-
particle stability was measured. As for gold nanoparticles, up to
5% (mol/mol) FluPep ligand incorporated into the ligand matrix
had no discernible effect on the handling and purification of the
silver nanoparticles. The silver nanoparticles did not bind non-
specifically to Sephadex G25, as they eluted in the void volume
and their UV–vis spectrum in PBS was indistinguishable from
that of control mixed-matrix silver nanoparticles (Figure 5A).
When challenged by a small thiol, DTT, the silver nanoparti-
cles passivated by the mixed-matrix ligand shell were some-
what more prone to ligand exchange than their gold counter-
parts. Thus, after 3 h and 6 h in 50 mM DTT a small increase in
aggregation parameter was apparent (Figure 5B). After 24 h and
48 h, the aggregation parameter started to rise at 3 mM DTT,
which was most pronounced at 48 h. Whereas an increase in
aggregation parameter indicates a loss of ligand shell integrity
and nanoparticle aggregation, the absolute value of aggregation
parameter greater than 1 is not informative, since nanoparticle
can aggregate in different ways that affect the UV-vis spectra
differently. Thus, the inclusion of 5% (mol/mol) FluPep ligand
in their ligand shell did not change the stability of the silver
nanoparticles with respect to DTT-mediated ligand exchange
(Figure 5C and Supporting Information File 1, Figure S4).
Purification of the FluPep-functionalised silver nanoparticles
was achieved by cation-exchange chromatography on
CM-Sepharose. As the percentage of FluPep incorporated into
Figure 5: Stability of silver nanoparticles to DTT ligand exchange.
(A) UV–vis spectra of mixed-matrix-capped silver nanoparticles and
mixed-matrix-capped silver nanoparticles incorporating 5% (mol/mol)
FluPep ligand in PBS. Time and dose-dependence of DTT ligand
exchange for (B) mixed-matrix silver nanoparticles and (C) silver nano-
particles incorporating different molar fractions of FluPep ligand.
Results are the mean ± SD (n = 3).
the ligand shell increased, so did the percentage of nanoparti-
cles bound to CM-Sepharose (Figure 6). This suggests that the
molar fraction of FluPep ligand in the initial mixture of
ligands added to the nanoparticles reflects its incorporation into
the ligand shell [26,30]. Thus, as for gold nanoparticles, when
10% of the total nanoparticle preparation bound to the
CM-Sepharose column, ca. 95% of the bound nanoparticles will
possess a single FluPep ligand [30]; at higher molar fractions of
FluPep ligand the silver nanoparticles will incorporate more
than one FluPep ligand.
Anti-influenza activity of FluPep ligand
incorporated to silver nanoparticles
Control mixed-matrix-passivated silver nanoparticles had no
effect on viral infectivity (Figure 7). It is the silver (Ag+) ions
that exert antimicrobial activity [33]. Thus, this result indicates
that there is not a substantial release of Ag+ ions from the silver
nanoparticles during the experiment. This concurs well with our
data (Figure 5) and previously reported observations [17]
demonstrating that the mixed-matrix ligand shell imparts good
Beilstein J. Nanotechnol. 2019, 10, 1038–1047.
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Figure 6: Purification of FluPep ligand-functionalised silver nanoparti-
cles by CM-Sepharose cation-exchange chromatography. Silver nano-
particles functionalised with different molar fractions of FluPep ligand
were subjected to chromatography on CM-Sepharose. Top: images of
columns after loading and washing with PBS. Bottom: quantification of
unbound (flow-through and PBS wash fractions) and bound (eluted
with 2 M NaCl) fractions as a percentage of the total nanoparticles
applied to the column. Results are the mean ± SD (n = 3).
Figure 7: Determination of the half maximal inhibitory concentration
(IC50) of silver nanoparticles functionalised with FluPep ligand. Inhibi-
tion of plaque formation as a function of the concentration of silver
nanoparticles functionalised with different molar fractions of FluPep
ligand. Results are the mean ± SD (n = 3).
stability to the silver nanoparticles. In contrast, functionalisa-
tion of silver nanoparticles with FluPep ligand caused a marked
reduction in number of plaques (Figure 7). As the molar frac-
tion of FluPep ligand in the ligand shell increased, so did the
antiviral activity of these particles (Figure 7). Around 10% of
silver nanoparticles functionalised with 0.03% (mol/mol)
FluPep ligand bind to the CM-Sepharose column, indicating
that the majority of these will carry just a single FluPep ligand
(Figure 6). These nanoparticles are as potent as free FluPep and
more potent than free FluPep ligand (inset of Figure 3 and
Table 2: IC50 values of silver nanoparticles functionalised with differ-
ent molar fractions of FluPep ligand.
mol % FluPep ligand IC50 (nM)
0.03% 0.14
0.1% 0.077
0.3% 0.056
1% 0.019
3% 0.016
5% 0.015
Figure 7B). Silver nanoparticles with a higher grafting density
of FluPep ligand (so functionalised with a higher mol %) had a
greater anti influenza virus activity than either of the free
peptides (inset of Figure 3 and Figure 7B).
Conclusion
We have demonstrated that FluPep, a peptide demonstrated to
inhibit effectively influenza A virus subtypes, including H1N1,
H3N2 and H5N1 [15] can be successfully incorporated into the
ligand shell of gold and silver nanoparticles. The FluPep-func-
tionalised nanoparticles have a greater antiviral activity than the
free peptide. The FluPep amino acid sequence is hydrophobic
and its solubilisation requires dimethyl sulfoxide (DMSO). Al-
though a useful solvent, its use in therapies is problematic due
to DMSO causing potential adverse reactions in some individ-
uals such as a sensation of burning, vesiculation, dryness of skin
and local allergic reactions [34-36]. PEGylation of peptides has
been successfully used to increase their solubility and in some
instances their biological half-life [37,38]. However, such modi-
fications may alter the activity of the peptide and can have side
effects due to cleavage products [39], and so whether this is a
viable route for FluPep remains to be determined. Conjugation
to nanoparticles is shown here to be another means to deliver
effectively and safely FluPep ligand with enhanced activity in a
solvent-free formulation.
In relation to the safety of a nanoparticle formulation of FluPep,
the fate of nanoparticles delivered in murid rodents has been ex-
amined [40-47] and shows transfer of nanoparticles to vascular
organs, including the brain. However, the concentrations of
nanoparticles used in these experiments are ca. 1000-fold higher
than used in the present work. Moreover, there is currently no
conclusive in vivo evidence that the nanoparticles cross the
blood–brain barrier. Incubation of peripheral blood mononu-
clear cells with citrate and mixed-matrix gold nanoparticles
demonstrates that the mixed-matrix ligand shell markedly
reduces the reaction of the peripheral blood mononuclear cells
to the nanoparticles [48]. Therefore, whilst it remains to be de-
termined experimentally, it would seem that the FluPep-func-
tionalised nanoparticles may well be safe to deliver to target
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organs such the upper respiratory tract, a primary target for
respiratory viruses including influenza. Although the mixed-
matrix ligand shell largely prevents the dissolution of the silver,
there are examples of ligand shells that allow solvent access to
the silver and so the dissolution of the silver, at least under lab-
oratory conditions [17]. Thus, it would be possible to design
silver nanoparticles that act through FluPep ligand and released
Ag+ ions. This would also reduce the potential for accumula-
tion of nanoparticles in the body during repeated use of a
FluPep-nanoparticle therapeutic. The pulmonary route to
deliver drugs against respiratory infections is well established,
so delivery of functionalised nanoparticles against flu viruses is
highly feasible. Therefore, a nanoparticle formation of FluPep
ligand or analogous peptides offers a route to new treatments
for influenza and other respiratory pathogens.
Experimental
Materials
Peptides FluPep WLVFFVIFYFFRRRKK, FluPep ligand
CVVVTAAAWLVFFVIFYFFRRRKK and the ligand shell
matrix peptidol CVVVT-ol were purchased from Peptide Pro-
tein Research (PPR Ltd, Hampshire, UK). The alkanethiol
ethylene glycol ligand, HS(CH2)11(OC2H4)4OH, was pur-
chased from Prochimia (ProChimia Surface Sp. z o.o., Sopot,
Poland). Gold nanoparticles of 9 nm diameter stabilized in
citrate buffer were purchased from British Biocell (BBInterna-
tional Ltd, UK) and silver nanoparticles of ca. 10 nm diameter
from nanoComposix Inc. (CA, USA). Nanosep filters with
10 kDa cut-off were from PALL (PALL Corp., Portsmouth, and
Hants, UK). UV–vis spectra (2 nm incremental steps) were
measured using a SpectraMax Plus spectrophotometer
(Molcular Devices, Wokingham, UK) and 384-well plates from
Corning (Lowell, US) and the concentration of gold nanoparti-
cles and of silver nanoparticles was determined at 450 nm [18]
and 392 nm [49], respectively.
Synthesis of FluPep functionalised
nanoparticles
Mixed-matrix l igands 70:30 (mol/mol)  CVVVT-ol/
HS(CH2)11(OC2H4)4OH were prepared as described [26] by
first diluting 35 µL CVVVT-ol (4 mM DMSO/H2O) with
35 µL ddH2O, and 6 µL HS(CH2)11(OC2H4)4OH (2 mM) with
6 µL EtOH and 18 µL H2O. Adding the two solutions together
yielded a 2 mM ligand solution of 70% (mol/mol) CVVVT-ol
and 30% (mol/mol) HS(CH2)11(OC2H4)4OH. To functionalise
the nanoparticles with FluPep ligand, this was incorporated into
the initial ligand mix at the molar fraction indicated in the
figure legends. The ligand mixture was added to 900 µL (gold
or silver) nanoparticles and vortex-mixed. Once mixed, 100 µL
of 10× phosphate-buffered saline (PBS: 137 mM NaCl,
3 mM KCl, l.8 mM Na2HPO4, 15 mM KH2PO4) with Tween-
20 (0.1% (v/v)) pH 7.4 was added to the gold nanoparticles [26]
and 10× (100 mM NaNO3, 20 mM HEPES with Tween-20
(0.1% (v/v)) pH 7.4 to the silver nanoparticles [17], vortex-
mixed and the (gold or silver) nanoparticles were placed on a
rotating wheel for 24 h. Nanoparticles were concentrated
10-fold using 10 kDa Nanosep centrifugal filters (PALL Corp.,
Portsmouth, Hants, UK). Samples were then centrifuged for
7 min at 10000 rpm (ca. 12,000g) and the gold nanoparticles
diluted with 1× PBST (PBS 0.05% (v/v) Tween-20) and silver
nanoparticles with 1× (100 mM NaNO3, 20 mM HEPES). In
the case of FluPep-functionalised nanoparticles, the separation
of free FluPep ligand (Mw = 2967 Da) required six washes, each
wash involving a 10-fold dilution of the nanoparticles on a
10 kDa cut-off Nanosep filter and centrifugation. The nanopar-
ticles were then further separated from excess ligands by
applying them (100 µL) to a 5 mL Sephadex G25 gel filtration
column with PBS as a mobile phase.
Ion-exchange chromatography
Ion-exchange chromatography was performed on custom-made
mini columns of diethylaminoethyl (DEAE) and carboxy-
methyl (CM) Sepharose (GE Healthcare Bio-Sciences AB,
Sweden). The gel slurry was packed into a white pipette tip
(200 µL) using half the filter as a frit and equilibrated in PBS.
Capped nanoparticles were concentrated and exchanged into
the appropriate buffer using a 10 kDa cut-off Nanosep
centrifugal filter. The nanoparticles were then applied to the
column, the unbound fraction was recovered. Columns were
washed with PBS and eluted with 1 M NaCl and then 2 M NaCl
in 8 mM Na2HPO4, 15 mM KH2PO4, pH 7.4.
Calculation of the aggregation parameter
(AP)
The surface plasmon absorption peak of 8.8 nm diameter
gold nanoparticles is at 520 nm. When gold nanoparticles
are aggregated, their surface plasmons couple causing a
red shift in their plasmon absorbance to approximately
650 nm. The aggregation parameter (AP) was defined as
(A650nm − Aref 650nm)/(A520nm−Aref 520), where A650nm and
A520nm are the absorbance of gold nanoparticles at 650 nm and
520 nm, respectively, and Aref 650nm and Aref 520 are the absor-
bance of water at 650 nm and 520 nm, respectively [27]. For
comparison of results, this primary stability parameter was
normalised by dividing the AP value of control ligand-capped
gold nanoparticles measured in milli Q water where [DTT] = 0.
For silver nanoparticle diameters of approximately 10 nm, the
surface plasmon absorption peak with a mixed-matrix ligand
shell is at 410 nm. The AP for silver nanoparticle was defined
as (A600nm − Aref 600nm)/(A410nm − Aref 410), where A600nm and
A410nm are the absorbance of Ag nanoparticles at 600 nm and
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410 nm, respectively and Aref 600nm and Aref 410 are the absor-
bance of water at 600 nm and 410 nm, respectively.
It is important to note that values of aggregation parameters
greater than 1 do not necessarily provide information on the
degree of aggregation of the nanoparticles, since completely
aggregated nanoparticles may exhibit different UV–vis spectra.
For example, small aggregates of nanoparticles that remain in
solution will show a red-shifted peak due to plasmon coupling,
whereas larger aggregates that may settle may present a feature-
less UV–vis spectrum.
Cell culture
Madin–Darby canine kidney epithelial cells [MDCK (ATCC
CRL-2936)] were grown in Dulbecco’s modified Eagle’s medi-
um (DMEM) supplemented with 5% (v/v) foetal calf
serum (FCS) (Labtech International Ltd, East Sussex, UK),
1% (v/v) 200 mM L-glutamine, 1% (v/v) 100 U/mL penicillin
and 1% (v/v) 100 µg/mL streptomycin (Gibco, Life Technolo-
gies, UK) and incubated in a humidified environment at 37 °C
under 5% (v/v) CO2 atmosphere. Cells were detached with
0.05% (w/v) trypsin in the chelating agent, 1× Versene-EDTA
(Gibco, Life Technologies, UK) and plated at a dilution of 1:4.
Preparation of influenza virus stock
MDCK cells were grown to 90% confluence in T25 tissue cul-
ture flasks (VWR, Lutterworth, Leicestershire, UK), which cor-
responds to 7 × 106 cells/flask. Then, the cell monolayer
was washed with 2 × 5 mL PBS, and virus (A/WSN/33 H1N1
subtype) was added at a multiplicity of infection (MOI) of
0.001 in 2 mL DMEM. Cells were incubated with virus for 1 h
at 37 °C on a rocking platform. Virus-containing medium
was removed and the cell monolayer washed with 2 × 5 mL
DMEM, then 5 mL N-acetyl trypsin (Sigma-Aldrich, Merck,
UK), 2.5 µg/mL in DMEM, was added and incubated for
24–48 hours at 37 °C until a significant cytopathic effect had
developed, to a point where the cells were lifting from the flask
substrate. Medium was removed and centrifuged for 5 min at
2500 rpm to remove cell debris and the supernatant, which
represented the viral stock, was stored at −80 °C.
Virus plaque assay
MDCK cells were grown in 6-well plates (STARLAB interna-
tional, Hamburg, Germany), 106 cells/well) for two days. At
confluence, monolayers of MDCK cells were then infected with
a serial dilution of influenza virus inoculum (sufficient to obtain
approximately 100 plaques per well) for 1 h at 37 °C on a
rocking platform. An agarose overlay was prepared by mixing
equal volumes of 2% (w/v) of pre-warmed (55 °C) low-melting
agarose (Melford Laboratories Ltd, Blideston Road, Ipswich,
UK) and the overlay solution (14 mL 10× MEM, 3.7 mL 7.5%
(w/v) bovine serum albumin (fraction V, Sigma-Aldrich, UK),
1.4 mL L-glutamine, 2.6 mL 7.5% (w/v) NaHCO2, 1.4 mL 1 M
HEPES, 1.4 mL (1% (v/v) 100 U/mL penicillin and
1% (v/v) 100 µg/mL streptomycin), 44.8 mL H2O and 5 µL
N-acetyl trypsin) to give a final 1% (w/v) agarose mixture.
After 1 h of incubation of the cells with the virus, the super-
natant was removed from the plates and overlaid with 2–3 mL
of the 1% (w/v) agarose overlay solution. The plates were left at
room temperature for 15 min for the overlay to solidify and then
inverted and placed in an incubator at 37 °C, 5% (v/v) CO2 for
3 days for plaques to develop. Cells were then fixed with 4 mL
10% (v/v) neutral buffered formalin (Leica Biosystems Peter-
borough Ltd, Bretton Peterborough, Cambridgeshire) for 1 h,
after which the formalin and overlay were removed and cells
were stained with 0.1% (w/v in water) toluidine blue, rinsed in
water, and left to dry before counting plaques.
Virus titre was determined for each preparation of virus. The
virus titre, as plaque-forming units (PFU) per mL, was deter-
mined by serially diluting the virus stock and counting the num-
ber of plaques in duplicate wells of MDCK cells. Only wells
containing between 10 and 100 plaques were counted to ensure
the assumption that each plaque formed was due to one infec-
tive virus particle was met.
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